NASDAQ:CCCC

C4 Therapeutics (CCCC) Stock Forecast, Price & News

$1.86

+0.02 (+1.09%)

(As of 09/29/2023 ET)

Compare

Today's Range: $1.85
▼
$1.97
50-Day Range: $1.81
▼
$3.89
52-Week Range: $1.72
▼
$10.42

Volume: 270,963 shs
Average Volume: 501,445 shs
Market Capitalization: $91.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.13

C4 Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 444.4% Upside
$10.13 Price Target
Short Interest: Bearish
5.94% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.29
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.69) to ($2.77) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

798th out of 972 stocks

Biological Products, Except Diagnostic Industry

130th out of 159 stocks

3.0

Analyst's Opinion

Consensus Rating
C4 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 3 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.13, C4 Therapeutics has a forecasted upside of 444.4% from its current price of $1.86.
Amount of Analyst Coverage
C4 Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.94% of the float of C4 Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
C4 Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in C4 Therapeutics has recently increased by 14.42%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
C4 Therapeutics does not currently pay a dividend.
Dividend Growth
C4 Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CCCC.

2.4

News and Social Media Coverage

News Sentiment
C4 Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for C4 Therapeutics this week, compared to 1 article on an average week.
Search Interest
6 people have searched for CCCC on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, C4 Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.97% of the stock of C4 Therapeutics is held by insiders.
Percentage Held by Institutions
74.88% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for C4 Therapeutics are expected to decrease in the coming year, from ($2.69) to ($2.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of C4 Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of C4 Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
C4 Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About C4 Therapeutics (NASDAQ:CCCC) Stock

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CCCC Price History

30 days | 90 days | 365 days | Advanced Chart

CCCC Stock News Headlines

September 27, 2023 | americanbankingnews.com

C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Rating of "Hold" by Analysts

September 21, 2023 | msn.com

C4 Therapeutics: Way Too Long A Wait For This One

September 30, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 5, 2023 | finance.yahoo.com

C4 Therapeutics Announces Chief Financial Officer Succession

August 28, 2023 | finance.yahoo.com

12 Best High Risk Penny Stocks to Buy Now

August 8, 2023 | finance.yahoo.com

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates

August 8, 2023 | finance.yahoo.com

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 4, 2023 | finance.yahoo.com

With 64% institutional ownership, C4 Therapeutics, Inc. (NASDAQ:CCCC) is a favorite amongst the big guns

September 30, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

July 17, 2023 | finance.yahoo.com

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 15, 2023 | finanznachrichten.de

C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 5, 2023 | marketwatch.com

C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance

July 5, 2023 | msn.com

C4 Therapeutics Explodes Higher on Lung Cancer News

July 5, 2023 | tmcnet.com

C4 Therapeutics Announces FDA Clearance of Investigational New

July 5, 2023 | benzinga.com

C4 Therapeutics Stock Is Surging: What's Going On?

July 5, 2023 | finance.yahoo.com

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

June 20, 2023 | finanznachrichten.de

C4 Therapeutics, Inc.: C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

June 20, 2023 | markets.businessinsider.com

C4 Therapeutics Appoints Leonard Reyno As CMO

June 20, 2023 | finance.yahoo.com

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

May 30, 2023 | msn.com

Evercore ISI Group Maintains C4 Therapeutics (CCCC) Outperform Recommendation

May 30, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for C4 Therapeutics

May 30, 2023 | tmcnet.com

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing

May 30, 2023 | finance.yahoo.com

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

May 14, 2023 | finance.yahoo.com

Broker Revenue Forecasts For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

May 12, 2023 | msn.com

Morgan Stanley Maintains C4 Therapeutics (CCCC) Underweight Recommendation

May 8, 2023 | msn.com

HC Wainwright & Co. Maintains C4 Therapeutics (CCCC) Buy Recommendation

May 8, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Their Buy Rating for C4 Therapeutics (CCCC)

See More Headlines

Receive CCCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CCCC Company Calendar

Last Earnings: 8/08/2023
Today: 9/30/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CCCC
CUSIP: N/A
CIK: 1662579
Web: www.c4therapeutics.com
Phone: 617-231-0700
Fax: N/A
Employees: 146
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.13
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +444.4%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.85)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-128,180,000.00
Net Margins: -872.34%
Pretax Margin: -872.34%
Return on Equity: -50.69%
Return on Assets: -33.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.69
Quick Ratio: 5.69

Sales & Book Value

Annual Sales: $31.10 million
Price / Sales: 2.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.91 per share
Price / Book: 0.31

Miscellaneous

Outstanding Shares: 49,190,000
Free Float: 45,270,000
Market Cap: $91.49 million
Optionable: Not Optionable
Beta: 2.07

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Andrew J. Hirsch M.B.A. (Age 52)
CEO, Pres & Director
Comp: $971k

Dr. Kenneth C. Anderson M.D. (Age 72)
Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board
Comp: $39.03k

Dr. Stewart Fisher (Age 56)
Chief Scientific Officer
Comp: $657.34k

Mr. Scott N. Boyle M.B.A. (Age 45)
Ph.D., Chief Bus. Officer
Comp: $672.78k

Dr. Nathanael S. Gray Ph.D.
Co-Founder & Member of Scientific Advisory Board

Ms. Lauren A. White M.B.A. (Age 44)
CFO & Treasurer

Ms. Kendra Adams
Sr. VP of Communications & Investor Relations

Ms. Jolie M. Siegel J.D. (Age 46)
Chief Legal Officer & Corp. Sec.

Ms. Kelly A. Schick (Age 43)
Chief People Officer

Dr. Isabel Chiu Ph.D.
Sr. VP of Strategic Alliances & Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CCCC Stock - Frequently Asked Questions

Should I buy or sell C4 Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CCCC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCCC, but not buy additional shares or sell existing shares.
View CCCC analyst ratings or view top-rated stocks.
What is C4 Therapeutics' stock price forecast for 2023?: 7 equities research analysts have issued 12 month target prices for C4 Therapeutics' stock. Their CCCC share price forecasts range from $5.00 to $20.00. On average, they expect the company's stock price to reach $10.13 in the next year. This suggests a possible upside of 444.4% from the stock's current price.
View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts.
How have CCCC shares performed in 2023?: C4 Therapeutics' stock was trading at $5.90 at the beginning of 2023. Since then, CCCC stock has decreased by 68.5% and is now trading at $1.86.
View the best growth stocks for 2023 here.
Are investors shorting C4 Therapeutics?: C4 Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 2,380,000 shares, an increase of 14.4% from the August 31st total of 2,080,000 shares. Based on an average daily trading volume, of 990,300 shares, the days-to-cover ratio is currently 2.4 days. Approximately 5.9% of the shares of the stock are short sold.
View C4 Therapeutics' Short Interest.
When is C4 Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CCCC earnings forecast.
How were C4 Therapeutics' earnings last quarter?: C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its earnings results on Tuesday, August, 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.01. The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $8.65 million. C4 Therapeutics had a negative net margin of 872.34% and a negative trailing twelve-month return on equity of 50.69%.

When did C4 Therapeutics IPO?: (CCCC) raised $150 million in an IPO on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.
What is C4 Therapeutics' stock symbol?: C4 Therapeutics trades on the NASDAQ under the ticker symbol "CCCC."
How do I buy shares of C4 Therapeutics?: Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is C4 Therapeutics' stock price today?: One share of CCCC stock can currently be purchased for approximately $1.86.
How much money does C4 Therapeutics make?: C4 Therapeutics (NASDAQ:CCCC) has a market capitalization of $91.49 million and generates $31.10 million in revenue each year. The company earns $-128,180,000.00 in net income (profit) each year or ($2.85) on an earnings per share basis.
How many employees does C4 Therapeutics have?: The company employs 146 workers across the globe.
How can I contact C4 Therapeutics?: The official website for the company is www.c4therapeutics.com. The company can be reached via phone at 617-231-0700 or via email at jane.urheim@sternir.com.

This page (NASDAQ:CCCC) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial